The type 2 diabetes (T2D) therapy market will expand over the first half of the 2021-2031 forecast period. This increase will be partly fueled by a rich pipeline of novel agents; emerging…
Metformin is the most heavily prescribed type 2 diabetes (T2D) drug and dominates the early lines of therapy before disease progression requires insulin replacement. The emergence of more-effective…
Intensive insulin regimens have been shown to delay the progression of complications associated with untreated or poorly treated type 1 diabetes (T1D). Therefore, it is unsurprising that insulins…
Clarivate Epidemiology’s coverage of type 1 diabetes (T1D) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the diagnosed incidence and…
Clarivate Epidemiology’s coverage of type 1 diabetes (T1D) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the diagnosed incidence and…
Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key type 1 diabetes patient populations covering 171 countries and more…
Clarivate Epidemiology’s coverage of type 1 diabetes (T1D) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the diagnosed incidence and…
Clarivate Epidemiology’s coverage of type 1 diabetes (T1D) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the diagnosed incidence and…
Clarivate Epidemiology’s coverage of type 1 diabetes (T1D) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the diagnosed incidence and…
Clarivate Epidemiology’s coverage of type 1 diabetes (T1D) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the diagnosed incidence and…
Clarivate Epidemiology’s coverage of type 1 diabetes (T1D) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the diagnosed incidence and…
The type 2 diabetes (T2D) therapy market will expand over the first half of the 2021-2031 forecast period. This increase will be partly fueled by a rich pipeline of novel agents; emerging therapies…
The next 10 years will be an exciting time in the type 1 diabetes (T1D) space as the number of treatment options continues to increase. Therapies in the late-phase pipeline represent drug classes…
EPI Data Slicer
Metformin and sulfonylureas are the most heavily prescribed type 2 diabetes (T2D) drugs; they dominate the early lines of therapy before disease progression requires insulin replacement. The…